News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tokai Pharmaceuticals Doses First Patient in a Phase 2 Study of Galeterone in Advanced Prostate Cancer



12/13/2012 10:15:21 AM

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tokai Pharmaceuticals, Inc., a biopharmaceutical company focused on developing new treatments for prostate cancer, today announced the treatment of the first patient in the ARMOR2 trial, a Phase 2 clinical study of its lead candidate galeterone (TOK-001) in patients with castration-resistant prostate cancer (CRPC). ARMOR2 is the second study in Tokai’s ARMOR (Androgen Receptor Modulation Optimized for Response) clinical development program for the evaluation of galeterone. Dosing occurred at the Urology Cancer Center and GU Research Network in Omaha, Neb. under the direction of Luke Nordquist, M.D., F.A.C.P.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES